Al-Ola A Abdallah MD (USMIRC) (@abdallah81md) ranks #5 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 40 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MajesTEC-9, MajesTEC-3, MagnetisMM-30. CMS Open Payments lists $344 in 2025 general payments.
At a Glance
- 26 posts naming a trial since ASH 2025
- 17 trials discussed by name
- Multiple Myeloma: US #5, Global #5 · 40 physicians engaged
- Leading physician voice: #1 of 3 physicians on BMS-986453; #1 of 3 physicians on MELT-MM
- CMS Open Payments lists $344 in 2025 general payments.
This Month
What Al-Ola A Abdallah MD (USMIRC) has posted in the last 30 days. Updated November 11, 2026.
🚨 The final AQUILA analysis #ASH2026 showed that early daratumumab improved both progression-free survival and overall survival in high-risk smoldering myeloma. At 7 years, overall survival was 87.8% with daratumumab versus 78.7% with active monitoring (HR 0.52). Here in Kansas this has been the SOC! #mmsm #myeloma #MedEd #USMIRC @USMIRCNEWS @Larvol @USMIRCNEWS @US_HMC @oncodaily @OpenMedKate
Who Amplifies Al-Ola A Abdallah MD (USMIRC)
Physicians who reposted Al-Ola A Abdallah MD (USMIRC)’s trial posts most often since ASH 2025.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #5 | #5 | 75/100 | 40 | 69 | Full ranking |
Trials Al-Ola A Abdallah MD (USMIRC) Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MajesTEC-9 | 3 | #8 of 16 | Jun 1, 2026 |
| MajesTEC-3 | 3 | #9 of 15 | Dec 10, 2025 |
| MagnetisMM-30 | 3 | — | Dec 7, 2025 |
| SUCCESSOR-2 | 2 | #6 of 15 | Jun 10, 2026 |
| AZD0120 | 2 | — | Dec 6, 2025 |
| JNJ-5322 | 2 | — | Nov 23, 2025 |
| AQUILA | 1 | #5 of 8 | Nov 5, 2026 |
| TRIlogy-1 | 1 | #4 of 5 | Oct 5, 2026 |
| BMS-986453 | 1 | #1 of 3 | Sep 27, 2026 |
| PERSEUS | 1 | #4 of 10 | Sep 26, 2026 |
| CERVINO | 1 | #5 of 11 | Sep 26, 2026 |
| MELT-MM | 1 | #1 of 3 | Sep 25, 2026 |
| anito-cel | 1 | #7 of 7 | Sep 24, 2026 |
| EXCALIBER-RRMM | 1 | #9 of 13 | Aug 14, 2026 |
| RedirecTT-1 | 1 | #5 of 10 | Dec 9, 2025 |
| CARTITUDE-4 | 1 | #9 of 9 | Dec 6, 2025 |
| inMMyCAR | 1 | #3 of 6 | Nov 25, 2025 |
Al-Ola A Abdallah MD (USMIRC) on MajesTEC-9
1/ 🧵 A Dominant Victory for BCMA: Teclistamab Scores Big in MajesTEC-9 from #ASCO26 Teclistamab moves earlier in RRMM! MajesTEC-9 evaluated teclistamab monotherapy vs PVd/Kd in patients with MM after 1–3 prior lines, all exposed to lenalidomide + anti-CD38 mAb. This is a https://t.co/GXJf1oRESX
10/ Bottom line for clinicians: MajesTEC-9 is practice-changing but not toxicity-free. Teclistamab earlier in relapse delivers deep responses and OS benefit, but infection prevention, IVIG, and thoughtful sequencing are essential. #mmsm #myeloma #USMIRC #MedEd #medtwitter
7/ 👏 Why this trial matters: MajesTEC-9 supports teclistamab as an effective earlier-line option for patients exposed/refractory to anti-CD38 and lenalidomide. This is exactly the population we are seeing more often after quadruplet frontline therapy. #mmsm #myeloma #USMIRC
Al-Ola A Abdallah MD (USMIRC) on MajesTEC-3
🧵 MajesTEC-3 Trial — Teclistamab + Daratumumab in RRMM A breakthrough Phase 3 trial reshaping post-lenalidomide treatment! #ASH25 #mmsm #Myeloma #MedEd #USMIRC @USMIRCNEWS @US_HMC @oncodaily @MedwatchKate @Larvol https://t.co/Ke5ixROqYV https://t.co/HrsrJZdrls
🧵 MajesTEC-3 Trial — Teclistamab + Daratumumab in RRMM A breakthrough Phase 3 trial reshaping post-lenalidomide treatment! 🔥 #ASH25 Wow and wow see the thread 🧵 and my critiques in tweet 6 1️⃣ Study Overview • RRMM pts with 1–3 prior LOT, all previously exposed to PI + LEN • https://t.co/hgAcGqcrdc
Finally I found the 10th abstract for #ASH25 🔥🔥🔥 Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of DPd/DVd in Pts with RRMM: majestec-3 1/ 🔥 Practice-changing data in RRMM! MajesTEC-3 is the first phase 3 trial of a BCMA×CD3 bispecific https://t.co/FLt9haCc28
Al-Ola A Abdallah MD (USMIRC) on MagnetisMM-30
🔥 Strong early signals from MagnetisMM-30 Part 1! Elranatamab + iberdomide delivered 95.5% ORR & 45.5% ≥CR in BCMA-naive RRMM, with mostly mild (≤ grade 2) TEAEs. Responses came fast—and kept improving. #ASH25 #mmsm #myeloma https://t.co/u3fFCbdDHK https://t.co/au7mZgbWEO
Impressive responses with elranatamab + iberdomide in MagnetisMM-30 💥 ORR 95.5%, median time to response 1.4 mo — deep responses observed early. Swimmer plots show durable benefit with ongoing responses, and dosing intensity maintained. Excited to see Part 2 progress! #ASH25 https://t.co/82D6FkpBXM
🤔 Safety profile for elranatamab + iberdomide in MagnetisMM-30 remains manageable 👀 Most TEAEs were hematologic, with CRS/ICANS all ≤ grade 2. Infections mostly grade ≤2; IVIG used to maintain IgG. Encouraging tolerability as studies progress. #ASH25 #Myeloma #BCMA #ASH25 https://t.co/usm3t6nv3E
Al-Ola A Abdallah MD (USMIRC) on SUCCESSOR-2
🔹 Is There Still a Place for Mezigdomide in the Modern Myeloma Treatment Landscape? Let’s see what data we have before we jump to conclusions? 🧵 ASCO 2026 | SUCCESSOR-2: Mezigdomide + Kd : 1/🔬 let’s start with the study Design (very Critical) SUCCESSOR-2 randomized RRMM https://t.co/fuF6cXsdc6
8/ 💭 Clinical Perspective & Remaining Questions SUCCESSOR-2 firmly establishes MeziKd as a highly active regimen in LEN- and anti-CD38-exposed RRMM. Key critiques: ▪️ Follow-up remains relatively short (10.6 months) ▪️ OS data are immature ▪️ High rates of neutropenia and
Al-Ola A Abdallah MD (USMIRC) on AZD0120
🚨 New data from ASCT-naïve NDMM CAR-T cohort! GC012F/AZD0120 shows 100% ORR, 97% MRD-sCR, and 100% MRD-negative rate 🙌 📈 Sustained MRD negativity = better survival 🛡️ Well-tolerated safety with long follow-up 💡 Broadened options for NDMM patients #ASH25 #CAR_T #Myeloma #MRD https://t.co/vmT6vBpwds
🔥 GC012F/AZD0120 continues to impress at #ASH2025! 🟣 100% ORR across both NDMM cohorts 🟣 Deep responses: 97% sCR 📊 Median follow-up: 36.5 months 💪 Strong PFS/OS signals with durable responses 🛡️ Safety: well-tolerated • Mostly low-grade CRS • No ICANS, IEC-HS, or delayed https://t.co/MVibBwWcWF
Al-Ola A Abdallah MD (USMIRC) on JNJ-5322
Abstract 9/10 #ASH25; From the world 🌍 1/🚨 Abstract #abs25-7875 🔥 Updated efficacy & safety data for JNJ-5322, a next-gen BCMA × GPRC5D × CD3 trispecific antibody for relapsed/refractory multiple myeloma (RRMM)! #ASH25 #Myeloma #Immunotherapy #mmsm #myeloma #MedEd
8/🏁 Conclusion JNJ-5322 shows CAR-T-like response rates with off-the-shelf convenience, Q4W dosing, and low grade ≥2 CRS — a promising approach for dual-antigen myeloma targeting. More data coming! 📈 #Myeloma #ASH25 #CancerResearch #mmsm #myeloma #MedEd #MedTwitter @US_HMC
Al-Ola A Abdallah MD (USMIRC) on AQUILA
🚨 The final AQUILA analysis #ASH2026 showed that early daratumumab improved both progression-free survival and overall survival in high-risk smoldering myeloma. At 7 years, overall survival was 87.8% with daratumumab versus 78.7% with active monitoring (HR 0.52). Here in Kansas this has been the SOC! #mmsm #myeloma #MedEd #USMIRC @USMIRCNEWS @Larvol @USMIRCNEWS @US_HMC @oncodaily @OpenMedKate
Al-Ola A Abdallah MD (USMIRC) on TRIlogy-1
📊 Ramantamig: Deep Responses, Durable Control & Outpatient Potential Updated phase I TRILogy-1 findings in triple-class exposed relapsed/refractory multiple myeloma are encouraging. Among 47 BCMA/GPRC5D-naïve patients treated at the recommended phase II dose: 🔹 93.6% overall https://t.co/w1Zy0GQC9J
Al-Ola A Abdallah MD (USMIRC)’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Watching those Tec/Dara vs Cilta-Cel PFS curves 👀📈 — honestly, a head-to-head RCT might be all we need to prove Tec/Dara has the edge… IMHO 🤷♂️🔥 #mmsm #myeloma #MedEd #MedTwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily https://t.co/ZFV0jFss4V
Two takeaways from #IMS26 #IMS2026: 1️⃣ Etentamig may be the BCMA bispecific to WIN: lower observed toxicity + monthly dosing could expand community use. 2️⃣ Dual targeting is where RRMM is headed. For now, trispecific antibodies appear ahead of dual-target CAR-T. Cross-trial
Outstanding approach to consider especially we are moving Tec upfront and in combination therapy and we need to consider fixed duration as well!! Congrats @GomezDLeonMD @ASH_hematology #ASH25 https://t.co/gXwJ6VPsfw
Every BCMA CAR-T company has eyes on this talk 👀. The arrival of in vivo CAR-T is an iPhone-moment — and we know how that ended for Nokia and Blackberry. 📉📈 #ASH25 @oncodaily #MedEd #MedTwitter #mmsm @DrPaulyDeSantis @RenoHemonc https://t.co/EizbF2E7y0 https://t.co/7KB2XGP2Vh
9/ The future role of MeziKd needs to be defined in: 🔹 Triple-class refractory disease 🔹 Post-CAR-T relapse 🔹 Post-BCMA refractory disease 🔹 Post-GPRC5D refractory disease As BCMA- and GPRC5D-directed therapies move earlier in treatment, demonstrating efficacy in these
Industry Payments
CMS Open Payments · 2025 general payments
$344 across 4 payments